Sinclair Pharma PLC AGM Statement (1735R)
June 13 2018 - 1:00AM
UK Regulatory
TIDMSPH
RNS Number : 1735R
Sinclair Pharma PLC
13 June 2018
Sinclair Pharma Plc
AGM statement
13 June 2018, Sinclair Pharma plc (AIM: SPH.L), ("Sinclair" or
the "Company") the international aesthetics company, will hold its
AGM at 10:00 am in London today and Grahame Cook, Chairman, will
make the following statement:
I am pleased to say that trading in the year to date is
progressing well. Momentum in our ex-US business remains strong
with the business on track to deliver mid-teens growth at constant
currency for 2018, which is in line with the guidance we provided
at the time of our full year results.
In April the Company created its own in-house sales force in the
US. While it is still early days the Board is very pleased with
sales in the first two months ahead of budget. Our direct customer
contact continues to give us confidence that the Silhouette
InstaLift(R) brand remains strong in the US and this is backed up
by recognition at congresses and publications within leading
industry journals in recent months. We believe prospects for the
product in the US remain strong and reiterate our guidance that US
sales will be at least GBP3.0 million (on a constant currency
basis) in the current financial year.
The recent launch of Ellansé(R) in Brazil has been a great
success with initial demand exceeding budget. The Company's first
LATAM World Experts Meeting took place in Rio de Janeiro on 11 May
and was attended by over 900 doctors from across the region.
Feedback on our products was very positive and following the
conference, we have since seen a substantial increase in physician
interest which has reinforced our view that the Brazil opportunity
is a very significant one for Sinclair.
We look forward to another year of robust growth in 2018. As
previously indicated sales are expected to be second half weighted
to a similar degree as in 2017 as a result of the switch to direct
sales in the US, the launch of Ellansé(R) in Brazil as well as
overall aesthetic market seasonality.
The Board believes that prospects for the Company have never
been stronger.
Sinclair expects to issue a trading update for the six months
ending 30 June 2018 in mid-July.
For further information, please contact:
Sinclair Pharma plc Tel: +44 (0) 20 7467 6920
Chris Spooner
Alan Olby
Andy Crane
Peel Hunt LLP (NOMAD and Joint Broker) Tel: +44 (0) 20 7418
8900
James Steel
Oliver Jackson
RBC Capital Markets (Joint Broker) Tel: +44 (0) 20 7653 4000
Marcus Jackson
Media enquiries
FTI Consulting Tel: +44 (0) 20 3727 1000
Ben Atwell
Brett Pollard
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the
fast growth, high gross margin, self-pay global aesthetics market.
Sinclair has built a strong portfolio of differentiated,
complementary aesthetics technologies, which are experiencing
significant growth, targeting unmet clinical needs for effective,
high quality, longer duration, natural looking and
minimally-invasive treatments. The Company is planning entry to
multiple new geographic markets and line extension launches over
the next few years. Sinclair has an established sales and marketing
presence in the leading EU markets, Brazil, South Korea and the US,
and has a network of international distributors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMFKBDPPBKDBAD
(END) Dow Jones Newswires
June 13, 2018 02:00 ET (06:00 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Jun 2023 to Jun 2024